Payment overview · 2025
General Payments
$825.58
40 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Darmadi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VANDALIA, IL · NPI 1184601577
Verified facts
What the public records show
CMS Open Payments records show Michael Darmadi, MD received $825.58 in general payments during 2025 across 40 reported records.
Novo Nordisk Inc accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $318.85 | 38.6% | 19 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $271.60 | 32.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.71 | 18.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.94 | 7.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.48 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $825.58 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $271.60 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.87 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.87 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $151.98 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.47 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.94 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 431 | 107 |
| Potassium Chloride | Potassium Chloride | 417 | 105 |
| Losartan Potassium | Losartan Potassium | 415 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 414 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 99 |
| Montelukast Sodium | Montelukast Sodium | 306 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 48 |
| Lisinopril | Lisinopril | 304 | 78 |
| Tramadol Hcl | Tramadol Hcl | 291 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 278 | 102 |
| Metformin Hcl | Metformin Hcl | 276 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 50 |
| Lorazepam | Lorazepam | 219 | 36 |
| Furosemide | Furosemide | 215 | 61 |
| Omeprazole | Omeprazole | 212 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 211 | 59 |
| Gabapentin | Gabapentin | 206 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 51 |
| Carvedilol | Carvedilol | 198 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 59 |
| Famotidine | Famotidine | 180 | 45 |
| Trazodone Hcl | Trazodone Hcl | 180 | 44 |
| Fenofibrate | Fenofibrate | 176 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 46 |
| Alprazolam | Alprazolam | 154 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 42 |
| Eliquis | Apixaban | 132 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 38 |
| Sucralfate | Sucralfate | 115 | 38 |
| Spironolactone | Spironolactone | 114 | 28 |
| Prednisone | Prednisone | 110 | 71 |
| Donepezil Hcl | Donepezil Hcl | 107 | 30 |
| Clonidine Hcl | Clonidine Hcl | 106 | 49 |
| Allopurinol | Allopurinol | 105 | 30 |
| Meloxicam | Meloxicam | 105 | 31 |
| Clonazepam | Clonazepam | 103 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 100 | 76 |
| Simvastatin | Simvastatin | 98 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 37 |
| Bupropion Hcl Sr | Bupropion Hcl | 95 | 24 |
| Ezetimibe | Ezetimibe | 90 | 28 |
| Lovastatin | Lovastatin | 88 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 18 |
| Cefdinir | Cefdinir | 82 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 57 |
| Januvia | Sitagliptin Phosphate | 76 | 13 |
| Pregabalin | Pregabalin | 71 | 18 |
| Jardiance | Empagliflozin | 70 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 47 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Megestrol Acetate | Megestrol Acetate | 57 | 13 |
| Ozempic | Semaglutide | 57 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 12 |
| Meclizine Hcl | Meclizine Hcl | 56 | 19 |
| Memantine Hcl | Memantine Hcl | 56 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 55 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Topiramate | Topiramate | 53 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 14 |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Levofloxacin | Levofloxacin | 50 | 37 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 14 |
| Xarelto | Rivaroxaban | 47 | 14 |
| Glimepiride | Glimepiride | 45 | 13 |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 22 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Celecoxib | Celecoxib | 40 | 13 |
| Temazepam | Temazepam | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Enulose | Lactulose | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 24 |
| Valacyclovir | Valacyclovir Hcl | 32 | 17 |
| Estradiol | Estradiol | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Cefprozil | Cefprozil | 30 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Roflumilast | Roflumilast | 23 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | 16 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $825.58 · 40 records | Novo Nordisk Inc | BREZTRI, JARDIANCE, Kerendia, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error